These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 19147676)

  • 1. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
    de Vries-van der Weij J; de Haan W; Hu L; Kuif M; Oei HL; van der Hoorn JW; Havekes LM; Princen HM; Romijn JA; Smit JW; Rensen PC
    Endocrinology; 2009 May; 150(5):2368-75. PubMed ID: 19147676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
    Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
    de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
    Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.
    Berti JA; Amaral ME; Boschero AC; Nunes VS; Harada LM; Castilho LN; Oliveira HC
    Metabolism; 2001 May; 50(5):530-6. PubMed ID: 11319713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice.
    Bijland S; van den Berg SA; Voshol PJ; van den Hoek AM; Princen HM; Havekes LM; Rensen PC; Willems van Dijk K
    J Lipid Res; 2010 Jan; 51(1):97-102. PubMed ID: 19564641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CETP expression reverses the reconstituted HDL-induced increase in VLDL.
    Wang Y; Berbée JF; Stroes ES; Smit JW; Havekes LM; Romijn JA; Rensen PC
    J Lipid Res; 2011 Aug; 52(8):1533-41. PubMed ID: 21606464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion.
    Harada LM; Amigo L; Cazita PM; Salerno AG; Rigotti AA; Quintão EC; Oliveira HC
    Atherosclerosis; 2007 Apr; 191(2):313-8. PubMed ID: 16806230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice.
    de Vries-van der Weij J; Zadelaar S; Toet K; Havekes LM; Kooistra T; Rensen PC
    Atherosclerosis; 2009 Sep; 206(1):153-8. PubMed ID: 19345354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression.
    van der Hoogt CC; de Haan W; Westerterp M; Hoekstra M; Dallinga-Thie GM; Romijn JA; Princen HM; Jukema JW; Havekes LM; Rensen PC
    J Lipid Res; 2007 Aug; 48(8):1763-71. PubMed ID: 17525476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice.
    Zhong S; Goldberg IJ; Bruce C; Rubin E; Breslow JL; Tall A
    J Clin Invest; 1994 Dec; 94(6):2457-67. PubMed ID: 7989603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
    Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesteryl ester transfer protein (CETP) increases postprandial triglyceridaemia and delays triacylglycerol plasma clearance in transgenic mice.
    Salerno AG; Patrício PR; Berti JA; Oliveira HC
    Biochem J; 2009 May; 419(3):629-34. PubMed ID: 19191759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
    Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
    Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice.
    de Haan W; de Vries-van der Weij J; Mol IM; Hoekstra M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
    Biochim Biophys Acta; 2009 Mar; 1791(3):191-7. PubMed ID: 19150509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
    van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
    J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance.
    Escolà-Gil JC; Julve J; Marzal-Casacuberta A; Ordóñez-Llanos J; González-Sastre F; Blanco-Vaca F
    J Lipid Res; 2001 Feb; 42(2):241-8. PubMed ID: 11181754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein lipase enhances the cholesteryl ester transfer protein-mediated transfer of cholesteryl esters from high density lipoproteins to very low density lipoproteins.
    Tall AR; Sammett D; Vita GM; Deckelbaum R; Olivecrona T
    J Biol Chem; 1984 Aug; 259(15):9587-94. PubMed ID: 6746661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
    Hurt-Camejo E; Gautier T; Rosengren B; Dikkers A; Behrendt M; Grass DS; Rader DJ; Tietge UJ
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.